Failure to Satisfy Listing Rule (Form 8-K)

Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.

On August 27, 2026, Jupiter Neurosciences, Inc. (the "Company") received a written notice (the "Notice") from the Listing Qualifications Department (the "Staff") of The Nasdaq Stock Market LLC ("Nasdaq") notifying the Company that the Staff had determined to delist the Company's common stock from The Nasdaq Capital Market. As previously notified by the Staff on February 26, 2026, the market value of the Company's listed securities had been below the minimum $35,000,000 required for continued listing under Nasdaq Listing Rule 5550(b)(2) for 30 consecutive trading days, and the Company was provided 180 calendar days, or until August 25, 2026, to regain compliance. The Notice states that the Company did not regain compliance with Nasdaq Listing Rule 5550(b)(2) or any of the alternative continued listing requirements under Nasdaq Listing Rule 5550(b).

The Company intends to timely appeal the Staff's determination by requesting a hearing before the Nasdaq Hearings Panel (the "Panel"). The Company expects that its hearing request will result in a stay of any further action pending the final hearing determination. However, there can be no assurance that the Company's appeal will be successful, that the Panel will grant the Company's request for continued listing, or that the Company will regain compliance with Nasdaq's continued listing requirements. The Company is considering all options available to it to regain compliance with all applicable listing rules.

Item 8.01 Other Events.

On August 27, 2026, the Company received a letter from the Staff notifying the Company that, for the 10 consecutive business days from August 13, 2026 through August 26, 2026, the closing bid price of the Company's common stock had been at least $1.00 per share and, accordingly, the Company had regained compliance with the minimum bid price requirement for continued listing on The Nasdaq Capital Market set forth in Nasdaq Listing Rule 5550(a)(2), and that the matter is now closed. As previously disclosed, on February 26, 2026, the Staff notified the Company that its common stock had failed to maintain a minimum bid price of $1.00 per share over the preceding 30 consecutive business days as required by Nasdaq Listing Rule 5550(a)(2). While the Company has regained compliance with the minimum bid price requirement, there can be no assurance that it will maintain compliance with that requirement or otherwise remain in compliance with Nasdaq's continued listing requirements.